Equillium, Inc. (NASDAQ:EQ) Short Interest Up 31.5% in December

Equillium, Inc. (NASDAQ:EQ) saw a significant increase in short interest in December. As of December 31st, there was short interest totalling 103,600 shares, an increase of 31.5% from the December 15th total of 78,800 shares. Currently, 0.6% of the company’s stock are short sold. Based on an average daily volume of 187,700 shares, the short-interest ratio is presently 0.6 days.

Equillium Price Performance

Shares of NASDAQ:EQ opened at $0.64 on Friday. The company’s 50-day moving average price is $0.71 and its two-hundred day moving average price is $0.82. Equillium has a one year low of $0.56 and a one year high of $3.25. The stock has a market capitalization of $22.81 million, a PE ratio of -4.60 and a beta of 1.78.

Institutional Trading of Equillium

An institutional investor recently raised its position in Equillium stock. Renaissance Technologies LLC increased its holdings in shares of Equillium, Inc. (NASDAQ:EQ) by 43.6% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 300,400 shares of the company’s stock after acquiring an additional 91,200 shares during the quarter. Renaissance Technologies LLC owned about 0.85% of Equillium worth $208,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 27.05% of the company’s stock.

About Equillium

Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.